Urinaryβ2-Microglobulin as a Possible Sensitive Marker for Renal Injury Caused by Tenofovir Disoproxil Fumarate
- 1 August 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 22 (8) , 744-748
- https://doi.org/10.1089/aid.2006.22.744
Abstract
Tenofovir disoproxil fumarate (TDF) is renally excreted by a combination of glomerular filtration and active tubular secretion, and its renal safety profiles have been reported based on a limited increase of serum creatinine (sCr) levels. However, renal tubular function has not previously been well monitored. We measured sCr and urinary β2-microglobulin (U-β2MG) levels cross-sectionally in 70 patients treated with TDF [TDF(+)] and 90 patients on other antiretroviral therapy who had never been exposed to TDF [TDF(−)]. The mean U-β2MG was significantly higher in TDF(+) patients than that in TDF(−) patients (p < 0.0001), though no statistical difference was detected in their creatinine clearance estimated by using the Cockcroft–Gault equation. Multivariate analysis showed that coadministration of boosted lopinavir (LPV) and patients’ body weight were associated with U-β2MG levels in TDF(+) patients. U-β2MG levels were significantly higher in those who also received boosted LPV [TDF(+)LPV(+)] (p = 0.0007), and abnormally high levels were noted in 67.7% of them. Furthermore, in the TDF(+)LPV(+) group, U-β2MG levels showed significant negative correlation with patients’ body weight (p = 0.0029) and abnormal U-β2MG was observed in all six patients with body weight less than 55 kg. In four patients, a rapid fall in U-β2MG occurred after cessation of TDF. Relative to sCr, U-β2MG could be a more sensitive marker of renal tubular injury caused by TDF. Boosted LPV co-administration and low body weight may be risk factors for TDF-induced renal tubular dysfunction, probably because these factors are associated with an increase in TDF concentration.Keywords
This publication has 27 references indexed in Scilit:
- Changes in Renal Function Associated with Tenofovir Disoproxil Fumarate Treatment, Compared with Nucleoside Reverse‐Transcriptase Inhibitor TreatmentClinical Infectious Diseases, 2005
- Proteomic-Based Identification of Cleaved Urinary β2-microglobulin as a Potential Marker for Acute Tubular Injury in Renal AllograftsAmerican Journal of Transplantation, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Renal safety of tenofovir in HIV treatment-experienced patientsAIDS, 2004
- Fanconi syndrome and acute renal failure in a patient treated with tenofovirAIDS, 2004
- Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-DidanosineClinical Infectious Diseases, 2003
- Abacavir Hypersensitivity ReactionClinical Infectious Diseases, 2002
- Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase InhibitorsAntimicrobial Agents and Chemotherapy, 2002
- Predictors of proteinuria and renal failure among women with HIV infectionKidney International, 2002
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976